![Pierre Kemula](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: - $ al 31/05/2026
El Sr. Pierre Kemula es Director Financiero de CureVac NV y Director Financiero de CureVac AG. Anteriormente, el Sr. Kemula fue Director Financiero de Pixium Vision SA y Vicepresidente de Tesorería, Mercados Financieros y Finanzas Corporativas de Ipsen SA. Se licenció en la London School of Economics & Political Science.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 18/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| AGOMAB THERAPEUTICS NV | Director Financiero/CFO | 01/11/2024 |
CureVac SE
 CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Director Financiero/CFO | 01/01/2016 |
| Empresas | Cargo | Fin |
|---|---|---|
| CUREVAC | Director Financiero/CFO | 31/10/2024 |
| PIXIUM VISION | Director Financiero/CFO | 16/02/2017 |
| IPSEN | Public Communications Contact | 01/01/2014 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 6 |
|---|---|
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
CureVac SE
CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Health Technology |
London School of Economics & Political Science
 London School of Economics & Political Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pixium Vision SA
 Pixium Vision SA Medical SpecialtiesHealth Technology Operates as a bioelectronics company that develops bionic vision systems | Health Technology |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV BiotechnologyHealth Technology Develops molecular therapies for regeneration of damaged tissues | Health Technology |
CureVac NV
 CureVac NV BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops medicines based on messenger ribonucleic acid which includes prophylactic vaccines, oncology, and molecular therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
